BMBhanu Chandra Mulukutla

Bhanu Chandra Mulukutla

*This is an algorithmically generated author record based on publicly available information.

Bhanu Chandra Mulukutla has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Cameron Harrington

    Upstream Process Development Biotherapeutics Pharm. Sci., Pfizer Inc. Andover Massachusetts USA

    5 shared publications
  • Taylor Kalomeris

    Cell Culture Process Development Pfizer Inc Andover Massachusetts USA

    4 shared publications
  • Gregory W. Hiller

    Cell Culture Process Development Pfizer Inc Andover Massachusetts USA

    3 shared publications
  • Michaela Jacobs

    Cell Culture Process Development Pfizer Inc Andover Massachusetts USA

    3 shared publications
  • Aparajita Dasgupta

    Manufacturing Sciences and Technology Pfizer Global Supply Andover Massachusetts USA

    2 shared publications
  • Carolyn Huang

    Bioprocess Research and Development Pfizer Research and Development Andover Massachusetts USA

    2 shared publications

Latest Publications

  • BioOps : Enabling MLOps for scalable and flexible model‐centric process control in biopharmaceutical development

    by Shu Yang, Edwin M. Shen, Piyush Agarwal, Amer Al Lozi, Isaac Snodgrass, Anas Husain, Victor Martins, Jordan Garry, Jennifer Klemisch, Mariah Brantley, et al.

    The deployment of advanced modeling and machine learning in biopharmaceutical process control has been limited by legacy fragmented automation infrastructure and a lack of model lifecycle governance. We present BioOps, a modular automation framework for biopharmaceutical advanced process control (APC). The framework incorporates established Machine Learning Operations (MLOps) principles, including version‐controlled model registries, containerized deployment, and continuous integration/continuous delivery (CI/CD) pipelines. BioOps explicitly decouples model development from model execution within the control architecture. This decoupling enables process scientists to deploy, test, and iteratively refine mathematical models and control strategies in a flexible manner. These workflows can be applied across heterogeneous bioreactor platforms and are executed entirely in‐house, without reliance on vendor‐specific solutions or custom system integration. In addition, BioOps embeds traceability, auditability, and model lifecycle management directly into the control stack. As a result, the framework aligns with regulatory expectations while continuing to support agile, in‐house experimentation and development. Case studies across a geographically distributed set of bioreactors demonstrate BioOps' versatility in PAT‐driven feedback control, hybrid model‐based nutrient and glucose feeding, adaptive phase transitions, and cross‐scale deployment. By operationalizing model‐centric control through an MLOps‐inspired architecture, BioOps provides a practical foundation for scalable, reproducible, and future‐ready biomanufacturing.

  • Open Access

    A Modular Mechanistic In Silico Model for In Vitro Transcription Process Yield and Product Quality Prediction

    by Keqi Wang, Keilung Choy, Eli Reiser, Jinxiang Pei, Hua Zheng, Aparajita Dasgupta, Fuqiang Cheng, Guogang Dong, Bhanu Chandra Mulukutla, Joshua Mannheimer, et al.

    In vitro transcription (IVT) plays a critical role in the manufacture of mRNA vaccines and therapeutics. Optimizing mRNA yield and ensuring product quality, such as capping efficiency and integrity, are essential but mechanistically complex. This study presents a modular mechanistic model of the IVT process to advance scientific understanding and improve predictive capability. The IVT reaction network is decomposed into interconnected modules describing (1) initiation and capping, (2) elongation and truncation, (3) termination and read‐through, (4) mRNA degradation, (5) magnesium pyrophosphate precipitation, and (6) enzymatic degradation of pyrophosphate. Guided by biochemical principles and experimental data, kinetic models were developed for each module, accounting for mass balances, molecular complexation, and enzyme activity, and were subsequently assembled to capture coupled IVT dynamics. Multivariate residual analysis and Shapley value‐based sensitivity analysis—guided by domain knowledge—were applied to iteratively improve model fidelity. These machine learning‐driven analytics enabled the identification of key mechanisms, supported in silico experimentation, and facilitated root‐cause analysis. Combined with Gaussian‐process‐based batch Bayesian optimization for efficient parameter estimation, this framework establishes a scalable hybrid (mechanistic + machine‐learning) modeling platform that integrates heterogeneous data, accelerates model calibration, and supports rational design and optimization of mRNA manufacturing processes.


  • Open Access

    A Modular Mechanistic In Silico Model for In Vitro Transcription Process Yield and Product Quality Prediction

    by Keqi Wang, Keilung Choy, Eli Reiser, Jinxiang Pei, Hua Zheng, Aparajita Dasgupta, Fuqiang Cheng, Guogang Dong, Bhanu Chandra Mulukutla, Joshua Mannheimer, et al.

    In vitro transcription (IVT) plays a critical role in the manufacture of mRNA vaccines and therapeutics. Optimizing mRNA yield and ensuring product quality, such as capping efficiency and integrity, are essential but mechanistically complex. This study presents a modular mechanistic model of the IVT process to advance scientific understanding and improve predictive capability. The IVT reaction network is decomposed into interconnected modules describing (1) initiation and capping, (2) elongation and truncation, (3) termination and read-through, (4) mRNA degradation, (5) magnesium pyrophosphate precipitation, and (6) enzymatic degradation of pyrophosphate. Guided by biochemical principles and experimental data, kinetic models were developed for each module, accounting for mass balances, molecular complexation, and enzyme activity, and were subsequently assembled to capture coupled IVT dynamics. Multivariate residual analysis and Shapley value-based sensitivity analysis, guided by domain knowledge, were applied to iteratively improve model fidelity. These machine learning-driven analytics enabled identification of key mechanisms, supported in silico experimentation, and facilitated root-cause analysis. Combined with Gaussian-process-based batch Bayesian optimization for efficient parameter estimation, this framework establishes a scalable hybrid (mechanistic + machine learning) modeling platform that integrates heterogeneous data, accelerates model calibration, and supports rational design and optimization of mRNA manufacturing processes.

  • Uncovering Growth‐Inhibitory Metabolic Byproducts in HEK293 Fed‐Batch Cultures and Strategies for Their Control

    by Cameron Harrington, Bhanu Chandra Mulukutla

    Human Embryonic Kidney 293 (HEK293) cells are currently one of the preferred host cell lines for the production of biologics, specifically, AAV‐based viral vectors. These fast‐growing cells consume significant amounts of nutrients and often convert them into byproducts such as lactate and ammonia. In fed‐batch cultures, accumulation of lactate and ammonia to high levels can inhibit cell proliferation. In this study, we demonstrate that lactate and ammonia accumulation alone doesn't fully explain the growth inhibition observed in HEK293 fed‐batch cultures. Growth inhibition was noted even when the residual levels of these byproducts were well controlled. Instead, we show that several previously unknown compounds accumulate in HEK293 cell fed‐batch cultures, some of which can inhibit HEK293 cell growth either individually or synergistically. Many of these newly identified compounds are intermediates or byproducts of amino acid catabolism. When residual levels of the source amino acids for these novel byproducts were controlled in the low concentration range (∼1 mM) in HEK293 fed‐batch cultures, lactate accumulated to higher levels, causing growth inhibition. This prompted the use of High‐end pH Delivery of Glucose (HIPDOG), a control strategy that limits lactate production by keeping low residual concentrations of glucose. In HIPDOG cultures, controlling the source amino acids at low concentrations resulted in lower accumulations of the corresponding growth‐inhibitory byproducts when compared to the control HIPDOG conditions with typical levels of amino acids. This led to higher viable cell densities (VCD) and viabilities in low amino acid conditions. Strategies that reduce byproduct accumulation, whether classical or novel byproducts, in HEK293 fed‐batch processes can result in enhanced VCDs, potentially leading to higher volumetric productivities.


  • Open Access

    Digging deeper into HEK293 metabolism: Growth inhibitory metabolic byproduct production in fed-batch cultures and their control

    by Cameron Harrington, Bhanu Mulukutla

    Not-yet-known not-yet-known not-yet-known unknown Human Embryonic Kidney 293 (HEK293) cells are currently one of the preferred host cell lines for production of biologics, specifically, AAV−based viral vectors. These fast-growing cells consume significant amounts of nutrients and often convert them into byproducts such as lactate and ammonia. In fed-batch cultures, accumulation of lactate and ammonia to high levels can inhibit cell proliferation. In this study, we demonstrate that lactate and ammonia accumulation alone doesn’t fully explain the growth inhibition observed in HEK293 fed-batch cultures. Growth inhibition was noted even when the levels of these byproducts were well controlled. Instead, we show that several previously unknown compounds accumulate in HEK293 cell fed-batch cultures, some of which can inhibit HEK293 cell growth either individually or synergistically. Many of these newly identified compounds are intermediates or byproducts of amino acid catabolism. When residual levels of the source amino acids for these novel byproducts were controlled in the low concentration range (~1mM) in HEK293 fed-batch cultures, lactate accumulated to higher levels, causing growth inhibition. This prompted the need for employing HIPDOG control strategy for lactate management. In HIPDOG cultures, controlling the source amino acids at low concentrations resulted in lower accumulations of the corresponding growth-inhibitory byproducts when compared to the control HIPDOG conditions with typical levels of amino acids. This led to higher viable cell densities (VCD) and viabilities in low amino acid conditions. Strategies that reduce byproduct accumulation, whether classical or novel byproducts, in HEK293 fed-batch processes can result in enhanced VCDs potentially leading to higher volumetric productivities

  • Metabolic engineering of CHO cells towards cysteine prototrophy and systems analysis of the ensuing phenotype

    by Laura Greenfield, Mariah Brantley, Pauline Geoffroy, Jeffrey Mitchell, Dylan DeWitt, Fang Zhang, Bhanu Chandra Mulukutla


  • Production of butyrate and branched‐chain amino acid catabolic byproducts by CHO cells in fed‐batch culture enhances their specific productivity

    by Cameron Harrington, Michaela Jacobs, Quentin Bethune, Taylor Kalomeris, Gregory W. Hiller, Bhanu Chandra Mulukutla

    Chinese hamster ovary (CHO) cells in fed‐batch cultures produce several metabolic byproducts derived from amino acid catabolism, some of which accumulate to growth inhibitory levels. Controlling the accumulation of these byproducts has been shown to significantly enhance cell proliferation. Interestingly, some of these byproducts have physiological roles that go beyond inhibition of cell proliferation. In this study, we show that, in CHO cell fed‐batch cultures, branched‐chain amino acid (BCAA) catabolism contributes to the formation of butyrate, a novel byproduct that is also a well‐established specific productivity enhancer. We further show that other byproducts of BCAA catabolism, namely isovalerate and isobutyrate, which accumulate in CHO cell fed‐batch cultures, also enhance specific productivity. Lastly, we show that the rate of production of these BCAA catabolic byproducts is negatively correlated with glucose uptake and lactate production rates. Thus, limiting glucose supply to suppress glucose uptake and lactate production, as in the case of fed‐batch cultures employing high‐end pH‐controlled delivery of glucose (HiPDOG) technology, significantly enhances BCAA catabolic byproduct accumulation, resulting in higher specific productivities.


  • Open Access

    Production of Butyrate and Branched Chain Amino Acid Catabolic Byproducts by CHO Cells in Fed-batch Culture Enhances their Specific Productivity

    by Cameron Harrington, Taylor Kalomeris, Michaela Jacobs, Gregory Hiller, Bhanu Chandra Mulukutla

    Chinese hamster ovary (CHO) cells in fed-batch cultures produce several metabolic byproducts derived from amino acid catabolism, some of which accumulate to growth inhibitory levels. Controlling the accumulation of these byproducts has been shown to significantly enhance cell proliferation. Interestingly, some of these byproducts have physiological roles that go beyond inhibition of cell proliferation. In this study, we show that, in CHO cell fed-batch cultures, branched chain amino acid (BCAA) catabolism contributes to the formation of butyrate, a novel byproduct that is also a well-established specific productivity enhancer. Further, the other byproducts of BCAA catabolism, isovalerate and isobutyrate, which accumulate in CHO cell fed-batch cultures also enhance specific productivity. Additionally, the rate of production of these BCAA catabolic byproducts was negatively correlated with glucose uptake and lactate production rates. Limiting glucose supply to suppress glucose uptake and lactate production, like in case of fed-batch cultures employing HiPDOG technology, significantly enhances BCAA catabolic byproduct accumulation resulting in higher specific productivities.

  • Open Access

    Lactate Control Enhances Growth Advantage in Fed-batch Cultures of Metabolically Engineered CHO Cells with Reduced Novel Growth-inhibitory Compound Formation

    by Quentin Bethune, Cameron Harrington, Bhanu Mulukutla

    CHO cells have been recently shown to produce amino acid catabolism derived byproducts, which accumulate in fed-batch cultures to growth-inhibitory levels. Residual amino acid limitation or genetic engineering strategies have been successfully employed to suppress production of these novel growth inhibitory metabolic byproducts. However, the growth advantage attained due to suppression of these metabolic byproducts in fed-batch cultures is more pronounced when lactate accumulation is also controlled. BCAT1 knock-out (KO) CHO cells, which produce negligible levels of the metabolic byproducts isovalerate, isobutyrate and 2-methylbutyrate, grow to significantly higher peak cell densities in fed-batch cultures with lactate control (HiPDOG) as compared to cultures without lactate control. Henceforth, strategies involving novel metabolic byproduct control should preferably include lactate control to more easily assess the enhanced cell growth and productivities attainable.


  • Metabolic engineering of Chinese hamster ovary cells towards reduced biosynthesis and accumulation of novel growth inhibitors in fed-batch cultures

    by Bhanu Chandra Mulukutla, Jeffrey Mitchell, Pauline Geoffroy, Cameron Harrington, Manisha Krishnan, Taylor Kalomeris, Caitlin Morris, Lin Zhang, Pamela Pegman, Gregory W. Hiller